Last edition
News about "Memorial Sloan Kettering Cancer Center"
Jideytro Wins US Approval for ROS1-Positive NSCLC
Jideytro (zidesamtinib) has won US approval for previously treated ROS1-positive NSCLC, backed by ARROS-1 trial results showing durable responses.
Memorial Sloan Kettering Cancer Center | 24/07/2026 | By News Bureau
Sophia Genetics Signs MoU with Memorial Sloan Kettering Cancer Center
Sophia Genetics has signed a strategic collaboration Memorandum of Understanding (MoU) with Memorial Sloan Kettering Cancer Center to establish a next-generation precision medicine hub.
Memorial Sloan Kettering Cancer Center | 08/06/2026 | By News Bureau | 153
AbbVie Receives FDA Approval for EPKINLY Combo in Relapsed/Refractory Follicular Lymphoma
AbbVie has secured FDA approval for EPKINLY in combination with rituximab and lenalidomide (EPKINLY + R2), marking the first bispecific antibody combo therapy available for patients with relapsed or refractory follicular lymphoma after at least one prior systemic treatment.
Memorial Sloan Kettering Cancer Center | 19/11/2025 | By Dineshwori | 181
Actinium Pharmaceuticals has entered a research collaboration with Memorial Sloan Kettering Cancer Center to expand Actimab-A’s mutation-agnostic mechanism in AML through targeted therapy combinations and patient-derived models.
Memorial Sloan Kettering Cancer Center | 20/03/2025 | By Aishwarya | 237
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy